A collection of PD neuropsychiatry experts recently published a thorough review article of anxiety in PD. They note that anxiety consistently ranks among the top 2 or 3 areas of unmet needs identified by people with Parkinson’s. The review discusses what we know—and don’t know—about phenomenology, etiology and treatment. It’s worth a read. Pontone, G.M., […]
The recently published study cited below shows evidence that various measurements of eye function (especially contrast sensitivity and the thickness of the inner plexiform layer in the retina) correlated very strongly with a summary measure of clinical variables associated with dementia risk in people with Parkinson disease (PD). We have long known that the back […]
Lumateperone is a new drug recently approved by the FDA for treatment of schizophrenia. The key clinical trial was just published and includes data on motor side effects of the drug. The sponsor, Intra-Cellular Therapies, Inc., may have data on use in Parkinson disease (PD), but I don’t think any of it is public. So […]
This web page describes our work, just published, that maps movement-related and non-movement-related effects of deep brain stimulation in Parkinson disease patients.
A recent article from CNN discussed Nuplazid® (pimavanserin), a medication approved by the FDA in 2016 for treatment of hallucinations or delusions in Parkinson’s disease (a.k.a. PDP, for Parkinson disease psychosis). The article made some efforts to present a balanced perspective, but the title and overall tenor of the article focused on the possibility that this new […]